This review provides a summary of key findings from 27 systematic reviews of 51 articles first published or indexed during 2015, focusing on the treatment of psoriasis and on precision medicine in psoriasis. The evidence supports weight-loss interventions by dieting and exercise for improvement in disease severity in overweight and obese patients with psoriasis. No significant increased risk of serious infections was reported for the biologic therapies adalimumab, etanercept and ustekinumab compared with appropriate comparators. Evidence could not provide reliable estimates of rare adverse events, emphasizing the need for large prospective registries. Polymorphisms in the tumour necrosis factor (TNF)-a gene may confer improved responses to TNF inhibitor (TNFI) therapy, but the studies to date lack power to detect a true association. From the limited available evidence, multidisciplinary management is both more effective and more satisfactory for patients with psoriasis and psoriatic arthritis than conventional consultations. This summary of reviews provides a succinct guide for clinicians and patients wishing to remain up to date with high-quality evidence for the treatment of psoriasis.
Background
The aim of this evidence update is to highlight the clinical findings from systematic reviews (SRs) published during 2015 on the treatment of psoriasis and on precision medicine in psoriasis. Details of the search methods used are provided in previous evidence updates on this subject [http://www.nottingham.ac.uk/research/groups/cebd/ resources/annual-evidence-updates.aspx].
Biologic therapies Safety of biologics
In an SR of 19 randomized controlled trials (RCTs) of the safety of adalimumab, etanercept and ustekinumab for moderate to severe psoriasis, Sorenson et al. did not show an increase in adverse events (AEs) such as serious infection compared with appropriate comparators. 1 However, the RCT evidence was too imprecise to provide reliable estimates of rare adverse events, emphasizing the need for large prospective registries such as the British Association of Dermatologists Biologics Intervention Register (BADBIR). 2 In an SR of 13 RCTs on the safety of adalimumab, etanercept and ustekinumab, Messori et al. infections. None of the indirect comparisons between active agents reached statistical significance, but for the endpoint of any serious AE (SAE), ustekinumab ranked first (i.e. safest). For the endpoint of infectious AE, lowdose etanercept ranked better than the other therapies.
Efficacy of biologics
Secukinumab is a human monoclonal antibody targeting interleukin (IL)-17A. In an SR of eight RCTs, Xiong et al. reported secukinumab to be highly effective compared with placebo at 12 weeks of therapy [Psoriasis Area and Severity Index reduction of 75% (PASI75); 150 mg dose schedule; OR = 49.25, statistically significant compared with placebo]. 4 The results of the metaanalysis (MA) reported no statistically significant increase in the incidence of SAEs with secukinumab therapy compared with placebo at 12 weeks of therapy, a finding that would be anticipated given the clinical trial powering for efficacy and the 12-week primary endpoint.
Efficacy and safety of biosimilars
An SR by Nast et al. 5 identified no trial data on biosimilar use in patients with psoriasis, but emphasized that RCTs of biosimilars of adalimumab, etanercept and infliximab were ongoing.
Biologics in the paediatric population
A Cochrane SR of the efficacy and safety of TNFI agents for paediatric psoriasis 6 found only one 12-week randomized, double-blind, placebo-controlled trial of etanercept use in patients (age range 4-17 years, median 13 years) with severe psoriasis suitable for inclusion. 7 At week 12, PASI75 was reached by 57% of participants taking etanercept versus 11% receiving placebo [risk ratio (RR) = 4.95, CI 2.83-8.65] with an increase in non-SAEs. This single trial meant that the authors could not make recommendations on the use of TNFI in the paediatric population, but drew attention to five further relevant trials in progress.
Biologic agent drug pipeline
An SR of the evidence for brodalumab, a monoclonal antibody directed against the IL-17 receptor, highlighted promising efficacy of its use in moderate to severe psoriasis in Phase III clinical trials. 8 However, its clinical trial programme was subsequently stopped for evaluation of an increase in suicidality among study participants. 
Fumaric acid esters
Oral fumaric acid esters (FAEs) are commonly used in the treatment of moderate to severe psoriasis. An SR of FAE use in psoriasis identified six RCTs meeting the inclusion criteria. 11 The MA, which included only two studies, reported that the number of participants attaining PASI 50 was greater with FAE treatment than with placebo (RR = 4.55-95% CI 2.8-7.4, P < 0.001). The authors acknowledged the low quality of the evidence from the included studies and highlighted inadequate reporting of AEs, which should be based on the Consolidated Standards of Reporting Trials. 12 
Maintenance of response to systemic and biologic treatments
In an SR of 25 studies of psoriasis therapies, Nast et al. reported pooled RRs for achieving PASI75 with systemic and biologic therapies for psoriasis, which comprised infliximab (RR = 13.07, 95% CI 8.06-19.87), secukinumab (RR = 11.97, 95% CI 8.83-16.23), ustekinumab (RR = 11.39, 95% CI 8.94-14.51), adalimumab (RR = 8.92, 95% CI 6.33-12.57), etanercept (RR = 8.39, 95% CI 6.74-10.45) and apremilast (RR = 5.83, 95% CI 2.58-13.17) at 24 weeks of treatment. 13 While highlighting the crucial point that effective long-term and safe strategies are required for ª 2018 British Association of Dermatologists the effective management of this chronic disease, the conclusions were limited because the definition of long-term therapy was only 24 weeks.
A further SR aimed to evaluate long-term treatment success through the assessment of rates of maintaining treatment response after successful induction therapy with either systemic or biologic therapy for patients with psoriasis.
14 However, high-quality data on ustekinumab therapy were omitted because patients in Phase III studies were re-randomized following induction at 9 months rather than the authors' chosen cut-off of 6 months. In an SR of 19 studies, the conclusions, including the suggestion that ciclosporin both at 5 mg/kg twice weekly or 3 mg/kg daily is effective in maintenance, were of limited clinical value.
Topical therapies
In an SR of 60 studies, Jacobi et al. highlighted the lack of well-designed studies to evaluate the use of topical treatments as adjuvant therapy in chronic plaque psoriasis. 15 The authors reported that regular use of emollients may reduce scaling and improve itch in patients with chronic plaque psoriasis, but concluded that there was no evidence to support their role in clearance of disease. Regarding keratolytic agents, salicylic acid was the beststudied compound, and results supported its use as monotherapy in scalp disease (as per NICE guidance 16 ).
Screening, monitoring, adherence, multidisciplinary management and comorbidities
Screening and monitoring
Ahn et al. highlighted the lack of high-quality evidence to support the use of screening and monitoring tests currently in practice for those prescribing systemic and biologic therapies for patients with psoriasis and PsA. 17 The authors reported increasing evidence to support hepatitis B virus (HBV) testing, given the possibility of refinement of management options based on specific HBV serology.
Adherence
It is well recognized that nonadherence to medication is common in the management of chronic plaque psoriasis, 18 and successful interventions to improve adherence would therefore be of benefit to this patient population. Depont et al. 19 conducted an SR of interventions to improve adherence in patients with any immune-mediated inflammatory disease (IMID), but of the 15 eligible studies, only 1 pilot study of patients with psoriasis 20 was included, thus the authors were unable to make conclusions regarding the effectiveness of interventions in this cohort. Vangeli et al. 21 considered the factors affecting nonadherence in the treatment of IMID in an SR that analysed 73 studies, including 11 studies of patients with psoriasis. The authors reported the strongest evidence for nonadherence across diseases related to psychosocial factors, yet these were least likely to be evaluated in psoriasis studies. The authors concluded that addressing treatment concerns, increasing understanding of treatment necessity and enhancing the relationship with the healthcare provider might facilitate adherence across diseases.
Cardiovascular risk in patients with psoriasis
Roubille et al. assessed the association between the incidence of cardiovascular events and the use of TNFI, MTX, nonsteroidal anti-inflammatory drugs or corticosteroids. 22 Six studies of patients with psoriasis and/or PsA met the inclusion criteria, but the results did not distinguish between those with either skin or joint disease alone, and the term 'systemic therapy' included studies on biologic therapy with TNFI as well as systemic agents e.g. MTX. The authors reported that systemic therapy versus no therapy or topical therapy was associated with a significantly decreased risk of all CVEs in psoriasis and/or PsA (RR = 0.75; 95% CI 0.63-0.91; P = 0.003).
Another SR considered whether use of oral MTX in the treatment of either psoriasis or rheumatoid arthritis conferred protection against CVEs. 23 The authors extrapolated their findings to conclude that MTX use was associated with lower rates of cardiovascular disease in patients with 'chronic inflammation', but no comment could be made regarding patients with psoriasis because the meta-analysis included only one historic study of patients with chronic plaque disease. 24 
Patient-reported outcomes
Kitchen et al. 25 considered the use of patient-reported outcome measures (PROMs) in relation to guidelines and clinical practice, providing a comprehensive and comprehensible review of the 16 psoriasis-specific English language PROMs in use. The authors concluded that no single PROM has adequate evidence of validity, reliability and sensitivity to change, or fully captures the emotional well-being and coping strategies of patients, and they suggested that a new assessment for psoriasis in clinical practice may be warranted.
Multidisciplinary management
Cobo-Ibanez et al. 26 aimed to analyse the efficacy of and satisfaction of with multidisciplinary dermatologyrheumatology management for patients with psoriasis and PsA. Their SR identified two case series with a retrospective analysis and one descriptive study, and concluded that from the limited available evidence, multidisciplinary management is both more effective and more satisfactory for patients with psoriasis and PsA than conventional consultations.
Other treatments/interventions Weight-loss interventions
An MA by Upala et al. aimed to evaluate the association between weight-loss interventions (diet and exercise) and improvement in disease severity in overweight and obese patients with psoriasis. 27 Seven RCTs involving 878 participants, 443 of whom were overweight or obese [body mass index (BMI) ≥ 25 kg/ m 2 ], were reviewed and 5 were included in the MA. The authors reported a pooled OR of 2.92 (95% CI 1.39-6.13, P = 0.005) for achieving PASI75 in participants receiving weight-loss intervention versus control in four of the studies, with a pooled mean difference across three studies of À2.49 (95% CI À3.90-1.08, P = 0.004) in reduction in PASI for participants receiving weight-loss intervention versus control.
Educational interventions for improving quality of life
An SR by Pickett et al. 28 considered the cost-effectiveness of educational interventions for improving health-related quality of life in patients with chronic inflammatory skin disease. Studies evaluated interventions that varied in terms of delivery modes (including group, face-to-face, online and text messaging), topics covered, provider and duration, and intensity of education. However, the poor quality and low number of included studies prevented conclusions on support for the clinical effectiveness or cost-effectiveness of these interventions.
Alternative therapies for psoriasis
Aloe vera is a species of succulent plant with a history of use as a topical application for various skin diseases. An SR of aloe vera for psoriasis that was limited to English-language studies found four RCTs of low to moderate quality, and was not able to come to any firm conclusions on efficacy despite the lack of significant AEs. 29 An SR to evaluate the efficacy and safety of acupuncture therapies for psoriasis identified six studies on a diverse range of interventions, such as acupuncture, bloodletting and moxibustion (a form of heat therapy using a preparation of Artemisia leaves). 30 Conflicting evidence from the highly heterogeneous studies and a global failure to report on health-related quality of life meant there was insufficient evidence to support the use of acupuncture therapies in the treatment of psoriasis.
The efficacy of Chinese herbal medicine, when used in conjunction with narrowband ultraviolet B phototherapy (NB-UVB), in the treatment of psoriasis, was assessed in an SR by Yang et al. 31 In total, 18 RCTs were included, which involved 1416 participants with psoriasis. Herbs with a high content of psoralens were not used in the included studies, and no two studies used the same herbal formula. The mean percentage of participants who achieved the outcome of PASI60 at treatment completion was 83% in the combination group and 59% in the NB-UVB group (RR = 1.35, 95% CI 1.26-45 P < 0.01), but quality of evidence was low according to Grading of Recommendations, Assessment, Development and Evaluations (GRADE), with common problems including a very short follow-up of study participants.
Precision medicine
Precision medicine refers to the tailored selection of treatment for an individual, based on factors such as their genetic makeup. Huang et al. 32 provided an SR of the literature concerning the role of small noncoding RNAs (microRNAs; miRNAs), which affect cellular function and whose role has been demonstrated to be important in skin homeostasis and inflammation. 33 They considered that, given the expanding field of personalised medicine, miRNAs might present the opportunity for the development of biomarkers of disease severity and treatment response.
Song et al. 34 considered the role of TNF-a polymorphisms in the response to TNFI therapy across IMIDs. The systematic review identified 10 papers, of which only 1 35 analysed a cohort of patients with psoriasis, thus their conclusion that white patients carrying specific TNF-a polymorphisms demonstrate improved responses to TNFI therapy has limited generalizability. Chen et al. 36 also included studies by Vasilopoulos et al. 35 and Gonzalez-Lara et al. 37 in their SR and MA of TNF receptor superfamily member 1B polymorphisms in ª 2018 British Association of Dermatologists the prediction of TNFI therapy. They concluded that the presence of the polymorphisms that were evaluated did not allow prediction of response. Both of these studies identified commonalities across IMIDs, but their conclusions were hampered by their inclusion of studies that were heterogeneous in terms of patient phenotyping and treatment types (multiple biologic therapies) and thus their conclusions were of limited value.
Conclusion
There has been a great increase in the number of SRs in the field of psoriasis since our previous evidence-based update in 2010, with a large increase in those related to biologic therapies, which have transformed the management of patients with moderate to severe disease. Focus on long-term management of patients with psoriasis with biologic therapy and their use in cohorts including children demonstrates progress in their use. There is a trend towards synthesis of evidence for patients with psoriasis and those across IMIDs. As well as relative merits, we must ensure that information is not extrapolated to our population of patients without care. Although systemic and biologic therapies form important treatments for patients with psoriasis, evidence supporting weight-loss interventions demonstrates our need to consider our patients holistically and adjust lifestyle factors where possible.
Learning points
• Over the past 5 years, clinicians have seen incredible change in the field of psoriasis, with increasing numbers of licenced approved biologic agents, an exciting drug pipeline and a rising interest in stratified medicine.
• Research suggest that weight-loss interventions in patients who are overweight or obese are associated with a reduction in disease severity.
• Licenced approved biologic therapies for moderate to severe chronic plaque psoriasis comprise monoclonal antibodies, which target TNF, IL12/ 23 and IL17A.
• Biologic therapies in development for the treatment of moderate to severe chronic plaque disease include monoclonal antibodies that target IL17R and IL23.
• Apremilast is an oral phosphodiesterase 4 inhibitor that was approved for use in moderate to severe psoriasis by NICE in November 2016.
• Oral methotrexate therapy in psoriasis reports no increased risk of lung disease (for treatment up to 52 weeks) and with regard to liver disease, an increased incidence of elevated transaminases but not of cirrhosis, liver failure or death.
